Detail akcie Aardvark Thera Rg online

Business Summary: Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Aardvark Therapeutics Inc revenues was not reported. Net loss increased from $11.8M to $40M. Higher net loss reflects PHARMACEUTICAL segment loss increase from $13.3M to $44M, United States segment loss increase from $13.3M to $44M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.55 to -$2.12.